Makers of Weight-Loss Drugs Want Your Employer to Pay for Them
On a spring day this year, the New Jersey State Policemen’s Benevolent Association received three unusual visitors: pharmaceutical representatives from Eli Lilly.Lilly’s reps presented a slide deck that laid out data on the effectiveness of Lilly’s weight-loss drug Zepbound.
The FDA’s risky action on compounding weight loss drugs
The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes former FDA Commissioner @ScottGottliebMD.
Rising Coverage for Weight-Loss Drugs Among U.S. Employers in 2024
In 2024, the percentage of U.S. employers covering weight-loss drugs has increased, with notable rises among larger employers. The trend, partly driven by new GLP-1 drugs, is influencing healthcare costs and accessibility.
Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment
The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.
Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.
What are your questions about weight loss drugs?
Weight loss and diabetes drugs Ozempic, Wegovy, Mounjaro and Zepbound are seen as game-changers for obesity and weight management but for many people, there are still questions around side effects, accessibility and results.
Employers Get Pressure to Pay for Drugs Like Wegovy
Eli Lilly and Novo Nordisk representatives get facetime with companies in hopes they will cover their weight-loss drugs.
Weight-loss drug coverage rises among largest US employers, Mercer survey finds
About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023, according to a survey from consulting firm Mercer released on Wednesday. Mercer also said 64% of U.
Weight loss drug makers still have huge upside, and the market overreacted to RFK Jr. named to top health role, BMO says
Investors are fearful RFK Jr.'s critical stance on weight loss drugs could impact pricing or Medicare coverage, but BMO says ...
Lost and found: Life after Ozempic and other weight-loss drugs was just the start for these four people
Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...
‘I Lost Over 50 Pounds From Zepbound—Here’s Why I Eventually Stopped Taking It’
When I lost weight on WW, I devoted all of my time to the program and I was successful. It was when life got hard that the food noise returned. So, my doctor and I decided to try Zepbound (tirzepatide ...
Yahoo1d
Doctors warn of potential dangers from weight loss injections
“But the widespread use for weight-loss drugs mimicking the FDA-approved versions has ... or as ‘tirzepatide,’ which is ...
KSL2d
Are Ozempic weight loss shots worth side effects? Do better options exist?
Today it is happening again with GLP1 agonists like Semaglutide with the brand names of Wegovy, Ozempic, and Rybelsus and similar drugs like Moujaro and Zepbound. And just like all the other ...
phillyvoice.com1d
Why is it so easy to regain weight after losing it? New research sheds light on the 'yo-yo effect'
MORE: Weight loss plans are less effective for many Black women − because ... Semaglutide is the drug in Ozempic and ...